Bioventus (NASDAQ:BVS – Get Free Report) and Sintx Technologies (NASDAQ:SINT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.
Insider & Institutional Ownership
62.9% of Bioventus shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 33.5% of Bioventus shares are held by company insiders. Comparatively, 4.1% of Sintx Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Bioventus and Sintx Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bioventus | $568.09 million | 1.94 | $22.73 million | $0.77 | 17.05 |
| Sintx Technologies | $1.08 million | 8.80 | -$10.36 million | ($4.91) | -0.45 |
Bioventus has higher revenue and earnings than Sintx Technologies. Sintx Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and price targets for Bioventus and Sintx Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bioventus | 0 | 1 | 5 | 0 | 2.83 |
| Sintx Technologies | 1 | 0 | 3 | 0 | 2.50 |
Bioventus currently has a consensus price target of $16.80, indicating a potential upside of 27.95%. Sintx Technologies has a consensus price target of $9.50, indicating a potential upside of 329.86%. Given Sintx Technologies’ higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Bioventus.
Profitability
This table compares Bioventus and Sintx Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bioventus | 9.36% | 28.08% | 9.82% |
| Sintx Technologies | -848.20% | -354.44% | -115.37% |
Summary
Bioventus beats Sintx Technologies on 11 of the 13 factors compared between the two stocks.
About Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
About Sintx Technologies
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
